Clinical trial
Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants With Interstitial Lung Disease Secondary to Systemic Sclerosis
NCT06195072 is registered in ClinicalTrials.gov with Scleroderma Research Foundation, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants With Interstitial Lung Disease Secondary to Systemic Sclerosis
- Lead sponsor
- Scleroderma Research Foundation, Inc.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- April 15, 2024
- Completion date
- November 30, 2026
- Enrollment
- 400 (estimated)
- Sites
- 34
Conditions
As the registry lists them; a condition with its own page is linked.
interstitial lung disease due to systemic disease, scleroderma